



or the group  $\text{NR}^3\text{R}^4$  or the group  $\text{NR}^5\text{R}^6$  may together represent a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O and  $\text{NR}^9$ ;

$\text{R}^7$  and  $\text{R}^8$  independently represent hydrogen or C1 to 6 alkyl; or the group  $\text{NR}^7\text{R}^8$  together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O and  $\text{NR}^9$ ;

$\text{R}^9$  represents hydrogen or C1 to 6 alkyl; said alkyl group being optionally further substituted by C1 to 6 alkoxy;

or a pharmaceutically acceptable salts thereof, in the manufacture of a medicament for the treatment or prophylaxis of diseases or conditions in which inhibition of kinase Itk activity is beneficial.

2. The use according to Claim 1 of a compound of formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of Th2-driven and/or mast cell-driven and/or basophil driven diseases or conditions.

3. The use according to Claim 2 wherein the disease is asthma.

4. The use according to Claim 2 wherein the disease is allergic rhinitis.

5. The use according to any one of Claims 1 to 4 wherein B in formula (I) represents CH and X represents O.

6. The use according to any one of Claims 1 to 5 wherein  $\text{R}^2$  in formula (I) represents  $-\text{CONR}^3\text{R}^4$  or  $\text{R}^2$  represents C1 to 6 alkyl substituted by  $\text{NR}^5\text{R}^6$ .

7. The use according to any one of Claims 1 to 4 wherein the compound of formula (I) is:

2-(4-chloro-2-hydroxyphenyl)-1,3-benzothiazole-6-carboxylic acid;

2-(2-hydroxy-6-methoxyphenyl)-1,3-benzothiazole-6-carboxylic acid;

5 2-(2-hydroxy-5-methoxyphenyl)-1,3-benzothiazole-6-carboxylic acid;

2-(4-chloro-2-hydroxyphenyl)-N-[2-(dimethylamino)ethyl]-N-methyl-1,3-benzothiazole-6-carboxamide;

5-chloro-2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

10 2-(4-chloro-2-hydroxyphenyl)-N-(3-morpholin-4-ylpropyl)-1,3-benzothiazole-6-carboxamide;

2-(4-chloro-2-hydroxyphenyl)-N-(2-pyrrolidin-1-ylethyl)-1,3-benzothiazole-6-carboxamide;

5-chloro-2-(6-{[4-(2-methoxyethyl)piperazin-1-yl]carbonyl}-1,3-benzothiazol-2-yl)phenol;

15 2-(2-hydroxy-5-methoxyphenyl)-N-(3-morpholin-4-ylpropyl)-1,3-benzothiazole-6-carboxamide;

4-methoxy-2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

2-(5-bromo-2-hydroxyphenyl)-N-[2-(dimethylamino)ethyl]-N-methyl-1,3-benzothiazole-6-carboxamide;

20 4-fluoro-2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

5-methoxy-2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

methyl N-{[2-(2-hydroxyphenyl)-1,3-benzothiazol-6-yl]carbonyl}serinate;

2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

25 2-(5-chloro-2-hydroxyphenyl)-N-(3-morpholin-4-ylpropyl)-1,3-benzothiazole-6-carboxamide;

3-methoxy-2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

N,N-diethyl-2-(2-hydroxy-4-methoxyphenyl)-1,3-benzothiazole-6-carboxamide;

N-[2-hydroxy-1-(hydroxymethyl)ethyl]-2-(2-hydroxy-4-methoxyphenyl)-1,3-benzothiazole-6-carboxamide;

30 2-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]pyridin-3-ol;

methyl 4-{[2-(6-{[2-(dimethylamino)ethyl](methyl)amino]carbonyl}-1,3-benzothiazol-2-yl)-3-hydroxyphenoxy]methyl}benzoate;

- 5-ethoxy-4-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]pyridin-3-ol;  
N-[2-(dimethylamino)ethyl]-2-(4-hydroxy-1,1'-biphenyl-3-yl)-N-methyl-1,3-benzothiazole-6-carboxamide;  
N-[2-(dimethylamino)ethyl]-2-(4-hydroxy-3'-methoxy-1,1'-biphenyl-3-yl)-N-methyl-1,3-benzothiazole-6-carboxamide;  
5-chloro-2-(6-{[[2-(dimethylamino)ethyl](methyl)amino]methyl}-1,3-benzothiazol-2-yl)phenol;  
5-chloro-2-(6-{[4-(2-methoxyethyl)piperazin-1-yl]methyl}-1,3-benzothiazol-2-yl)phenol;  
5-chloro-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
4-fluoro-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
3-methoxy-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
4-methoxy-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
4-bromo-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
5-methoxy-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
4-chloro-2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
2-{6-[(diethylamino)methyl]-1,3-benzothiazol-2-yl}-5-methoxyphenol;  
5-ethoxy-4-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]pyridin-3-ol;  
4-chloro-2-(6-{[(3-morpholin-4-ylpropyl)amino]methyl}-1,3-benzothiazol-2-yl)phenol;  
2-[6-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]pyridin-3-ol;  
2-[5-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
5-chloro-2-[6-(piperidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
5-chloro-2-[6-(4-methylpiperazin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;  
5-chloro-2-{6-[(diethylamino)methyl]-1,3-benzothiazol-2-yl}phenol;  
5-chloro-2-{6-[(dimethylamino)methyl]-1,3-benzothiazol-2-yl}phenol;  
2-[6-(hydroxymethyl)-1,3-benzothiazol-2-yl]phenol;  
2-(6-amino-1,3-benzothiazol-2-yl)-4-methoxyphenol;  
*N,N*-dimethyl-2-(2-hydroxy-4-methoxyphenyl)-1,3-benzothiazole-6-carboxamide;  
*N,N*-dimethyl-2-(2-hydroxyphenyl)-1,3-benzothiazole-6-carboxamide;  
3-[6-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]pyrazin-2-amine;  
2-(4-chloro-2-hydroxyphenyl)-1,3-benzothiazol-6-ol;  
5-chloro-2-[6-(2-hydroxy-3-pyrrolidin-1-yl-propoxy)-1,3-benzothiazol-2-yl]-phenol;

5-chloro-2-[5-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

2-[5-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazol-2-yl]phenol;

*N,N*-dimethyl-2-(2-hydroxyphenyl)-1,3-benzothiazole-5-carboxamide;

5-chloro-2-[5-(pyrrolidin-1-ylmethyl)-1,3-benzothiazol-2-yl]phenol;


5 2-{5-[(dimethylamino)methyl]-1,3-benzothiazol-2-yl}phenol;

2-(2-hydroxyphenyl)-*N*-(3-morpholin-4-ylpropyl)-1,3-benzothiazole-7-carboxamide;

or a pharmaceutically acceptable salt of any one thereof.

8. A compound of formula (Ia)

10



(Ia)

wherein:

15 A and D independently represent CH or N; and

either B represents CH and X represents O;

or B represents N and X represents NH;

20

$R^1$  represents hydrogen, halogen, C1 to 6 alkyl, C1 to 6 alkoxy, aryl or benzyloxy; said aryl or benzyloxy group being optionally further substituted by a group selected from C1 to 6 alkyl, C1 to 6 alkoxy, halogen and carbomethoxy;

$R^2$ , which is attached to the 5- or 6-position of the benzothiazole ring, represents  $CONR^3R^4$  or C1 to 6 alkyl or C1 to 6 alkoxy; said alkyl or alkoxy group being further substituted by one or more groups independently selected from hydroxy and  $NR^5R^6$ ;

- 5  $NR^3R^4$  represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O and  $NR^9$ ;

$R^5$  and  $R^6$  each independently represent hydrogen or C1 to 6 alkyl; said alkyl group being optionally further substituted by one or more substituents selected independently from  
10 hydroxy, C1 to 6 alkoxy,  $NR^7R^8$  and C1 to 6 alkoxycarbonyl;

or the group  $NR^5R^6$  together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O and  $NR^9$ ;

- 15  $R^7$  and  $R^8$  independently represent hydrogen or C1 to 6 alkyl; or the group  $NR^7R^8$  together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O and  $NR^9$ ;

$R^9$  represents hydrogen or C1 to 6 alkyl; said alkyl group being optionally further  
20 substituted by C1 to 6 alkoxy;

or a pharmaceutically acceptable salts thereof.


9. A compound of formula (Ia), according to Claim 8, for use as a medicament.

25

10. A pharmaceutical formulation comprising a compound of formula (Ia), as defined in Claim 8, or a pharmaceutically acceptable salt thereof, optionally in admixture with a pharmaceutically acceptable diluent or carrier.


11. A process for the preparation of a compound of formula (Ia), as defined in Claim 8, and optical isomers, racemates and tautomers thereof and pharmaceutically acceptable salts thereof, which comprises:

(a) reaction of a compound of formula (II)



(II)


wherein  $R^1$ , A, B, D and X are as defined in Claim 8, with a compound of formula (III)



(III)

wherein  $R^2$  is as defined in Claim 8; or

(b) oxidative cyclisation of a compound of formula (IV)



(IV)

wherein  $R^1$ ,  $R^2$ , A, B, D and X are as defined in Claim 8;

and where desired or necessary converting the resultant compound of formula (Ia), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (Ia) into another compound of formula (Ia); and where desired converting the  
s resultant compound of formula (Ia) into an optical isomer thereof.